Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
16.27
-0.24 (-1.45%)
At close: Jan 2, 2026, 4:00 PM EST
16.40
+0.13 (0.80%)
After-hours: Jan 2, 2026, 6:39 PM EST
Denali Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
422
Market Cap
2.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 330.53M | 222.07M | 204.74% |
| Dec 31, 2022 | 108.46M | 59.80M | 122.90% |
| Dec 31, 2021 | 48.66M | -287.00M | -85.50% |
| Dec 31, 2020 | 335.66M | 308.98M | 1,158.19% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
DNLI News
- 3 days ago - The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II) - GlobeNewsWire
- 23 days ago - Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment - Seeking Alpha
- 23 days ago - Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 24 days ago - Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 4 weeks ago - Denali Therapeutics Inc. (DNLI) Analyst/Investor Day Transcript - Seeking Alpha
- 4 weeks ago - Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement - GlobeNewsWire
- 4 weeks ago - Denali: Regulatory Delay Is A Strategic Opportunity - Seeking Alpha
- 5 weeks ago - Denali Therapeutics Inc. (DNLI) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha